CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
34.11
0.09%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.17
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Vericel Corp ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 34.14
Open* 33.76
1-Year Change* 36.62%
Day's Range* 33.76 - 34.11
52 wk Range 17.30-39.90
Average Volume (10 days) 259.04K
Average Volume (3 months) 7.79M
Market Cap 1.57B
P/E Ratio -100.00K
Shares Outstanding 47.64M
Revenue 178.18M
EPS -0.28
Dividend (Yield %) N/A
Beta 1.76
Next Earnings Date Nov 7, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 21, 2023 34.14 1.38 4.21% 32.76 34.45 32.76
Sep 20, 2023 32.46 -0.50 -1.52% 32.96 34.10 32.42
Sep 19, 2023 33.63 0.66 2.00% 32.97 33.98 32.97
Sep 18, 2023 33.91 -0.03 -0.09% 33.94 34.13 33.27
Sep 15, 2023 34.23 -0.69 -1.98% 34.92 35.63 34.02
Sep 14, 2023 35.67 -1.01 -2.75% 36.68 36.82 35.48
Sep 13, 2023 36.68 0.17 0.47% 36.51 37.71 36.51
Sep 12, 2023 36.46 4.02 12.39% 32.44 36.79 32.44
Sep 11, 2023 34.03 1.52 4.68% 32.51 34.18 32.51
Sep 8, 2023 32.65 0.61 1.90% 32.04 32.77 32.04
Sep 7, 2023 32.82 0.74 2.31% 32.08 33.73 32.06
Sep 6, 2023 33.44 1.37 4.27% 32.07 33.49 32.06
Sep 5, 2023 32.50 -0.82 -2.46% 33.32 33.36 32.15
Sep 1, 2023 33.83 1.03 3.14% 32.80 33.95 32.80
Aug 31, 2023 32.79 0.63 1.96% 32.16 33.16 32.16
Aug 30, 2023 32.50 0.59 1.85% 31.91 32.57 31.91
Aug 29, 2023 32.24 0.33 1.03% 31.91 32.52 31.91
Aug 28, 2023 32.02 0.28 0.88% 31.74 32.98 31.74
Aug 25, 2023 32.43 0.27 0.84% 32.16 32.95 32.14
Aug 24, 2023 32.31 -0.45 -1.37% 32.76 32.91 32.09

Vericel Corp Ord Events

Time (UTC) Country Event
Tuesday, November 7, 2023

Time (UTC)

13:30

Country

US

Event

Q3 2023 Vericel Corp Earnings Release
Q3 2023 Vericel Corp Earnings Release

Forecast

-

Previous

-
Wednesday, February 21, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 Vericel Corp Earnings Release
Q4 2023 Vericel Corp Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 164.365 156.184 124.179 117.85 90.857
Revenue 164.365 156.184 124.179 117.85 90.857
Cost of Revenue, Total 54.577 50.159 39.951 37.571 32.16
Gross Profit 109.788 106.025 84.228 80.279 58.697
Total Operating Expense 181.423 164.038 121.807 129.101 95.604
Selling/General/Admin. Expenses, Total 106.903 97.592 68.836 61.139 49.007
Research & Development 19.943 16.287 13.02 30.391 13.599
Unusual Expense (Income) 0 0 0.838
Operating Income -17.058 -7.854 2.372 -11.251 -4.747
Interest Income (Expense), Net Non-Operating 0.975 0.22 0.685 1.606 -3.359
Other, Net 0.095 0.052 -0.013 -0.02 -0.031
Net Income Before Taxes -15.988 -7.582 3.044 -9.665 -8.137
Net Income After Taxes -16.709 -7.471 2.864 -9.665 -8.137
Net Income Before Extra. Items -16.709 -7.471 2.864 -9.665 -8.137
Net Income -16.709 -7.471 2.864 -9.665 -8.137
Total Adjustments to Net Income 0
Income Available to Common Excl. Extra. Items -16.709 -7.471 2.864 -9.665 -8.137
Income Available to Common Incl. Extra. Items -16.709 -7.471 2.864 -9.665 -8.137
Diluted Net Income -16.709 -7.471 2.864 -9.665 -8.137
Diluted Weighted Average Shares 47.13 46.472 47.282 44.18 40.242
Diluted EPS Excluding Extraordinary Items -0.35453 -0.16076 0.06057 -0.21876 -0.2022
Diluted Normalized EPS -0.35453 -0.16076 0.06057 -0.21876 -0.18138
Total Extraordinary Items
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 45.922 41.017 52.694 38.551 37.046
Revenue 45.922 41.017 52.694 38.551 37.046
Cost of Revenue, Total 15.981 14.497 14.445 13.318 14.192
Gross Profit 29.941 26.52 38.249 25.233 22.854
Total Operating Expense 51.883 49.194 46.609 45.339 46.128
Selling/General/Admin. Expenses, Total 30.649 29.485 26.919 26.975 27.144
Research & Development 5.253 5.212 5.245 5.046 4.792
Operating Income -5.961 -8.177 6.085 -6.788 -9.082
Interest Income (Expense), Net Non-Operating 0.946 0.694 0.54 0.237 0.128
Other, Net -0.005 -0.012 -0.003 -0.005 -0.009
Net Income Before Taxes -5.02 -7.495 6.622 -6.556 -8.963
Net Income After Taxes -5.02 -7.495 5.922 -6.577 -8.963
Net Income Before Extra. Items -5.02 -7.495 5.922 -6.577 -8.963
Net Income -5.02 -7.495 5.922 -6.577 -8.963
Income Available to Common Excl. Extra. Items -5.02 -7.495 5.922 -6.577 -8.963
Income Available to Common Incl. Extra. Items -5.02 -7.495 5.922 -6.577 -8.963
Diluted Net Income -5.02 -7.495 5.922 -6.577 -8.963
Diluted Weighted Average Shares 47.572 47.387 47.232 47.182 47.117
Diluted EPS Excluding Extraordinary Items -0.10552 -0.15817 0.12538 -0.1394 -0.19023
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.10552 -0.15817 0.12538 -0.1394 -0.19023
Total Adjustments to Net Income
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 186.866 158.462 123.56 111.655 112.783
Cash and Short Term Investments 119.538 103.398 75.807 69.718 82.924
Cash & Equivalents 51.067 68.33 33.62 26.889 18.286
Total Receivables, Net 46.539 37.437 34.504 32.168 23.454
Accounts Receivable - Trade, Net 46.539 37.437 34.504 32.168 23.454
Total Inventory 15.986 13.381 9.356 6.816 3.558
Other Current Assets, Total 4.803 4.246 3.893 2.953 2.847
Total Assets 273.003 243.705 205.608 153.238 118.689
Property/Plant/Equipment, Total - Net 57.372 59.028 57.738 32.247 5.906
Property/Plant/Equipment, Total - Gross 75.674 73.35 69.124 41.467 13.411
Accumulated Depreciation, Total -18.302 -14.322 -11.386 -9.22 -7.505
Intangibles, Net 7.5
Total Current Liabilities 37.463 26.052 22.483 19.795 14.792
Accounts Payable 16.93 9.016 6.755 6.345 7.108
Accrued Expenses 20.492 16.995 15.687 13.409 6.93
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.041 0.041 0.041 0.041 0
Other Current Liabilities, Total 0.754
Total Liabilities 80.731 73.243 71.348 42.147 16.458
Total Long Term Debt 0 0.044 0.076 0.11 0
Long Term Debt 0
Other Liabilities, Total 43.268 47.147 48.789 22.242 1.666
Total Equity 192.272 170.462 134.26 111.091 102.231
Preferred Stock - Non Redeemable, Net
Common Stock 593.245 553.902 510.061 489.749 471.18
Retained Earnings (Accumulated Deficit) -399.995 -383.286 -375.815 -378.679 -368.91
Treasury Stock - Common
Total Liabilities & Shareholders’ Equity 273.003 243.705 205.608 153.238 118.689
Total Common Shares Outstanding 47.253 46.88 45.804 44.864 43.578
Total Preferred Shares Outstanding
Short Term Investments 68.471 35.068 42.187 42.829 64.638
Other Equity, Total -0.978 -0.154 0.014 0.021 -0.039
Long Term Investments 19.962 25.687 24.099 9.247
Other Long Term Assets, Total 1.303 0.528 0.211 0.089
Capital Lease Obligations 0 0.044 0.076 0.11
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 177.545 186.866 166.375 155.094 151.88
Cash and Short Term Investments 119.276 119.538 110.94 100.692 100.547
Cash & Equivalents 61.834 51.067 65.216 56.054 55.659
Short Term Investments 57.442 68.471 45.724 44.638 44.888
Total Receivables, Net 38.359 46.539 34.296 33.664 31.855
Accounts Receivable - Trade, Net 38.359 46.539 34.296 33.664 31.855
Total Inventory 15.37 15.986 16.729 15.929 14.385
Other Current Assets, Total 4.54 4.803 4.41 4.809 5.093
Total Assets 265.096 273.003 248.017 244.815 240.288
Property/Plant/Equipment, Total - Net 59.048 57.372 58.546 59.502 59.104
Property/Plant/Equipment, Total - Gross 78.25 75.674 75.81 75.752 74.299
Accumulated Depreciation, Total -19.202 -18.302 -17.264 -16.25 -15.195
Long Term Investments 19.91 19.962 21.739 23.718 22.803
Other Long Term Assets, Total 1.249 1.303 1.357 6.501 6.501
Total Current Liabilities 28.753 37.463 27.004 25.014 21.731
Accounts Payable 11.125 16.93 8.113 9.684 7.75
Accrued Expenses 17.608 20.492 18.85 15.289 13.94
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.02 0.041 0.041 0.041
Total Liabilities 71.118 80.731 70.18 69.999 67.803
Total Long Term Debt 0 0 0 0.021 0.019
Capital Lease Obligations 0 0 0.021 0.019
Other Liabilities, Total 42.365 43.268 43.176 44.964 46.053
Total Equity 193.978 192.272 177.837 174.816 172.485
Common Stock 602.104 593.245 584.9 575.011 563.475
Retained Earnings (Accumulated Deficit) -407.49 -399.995 -405.917 -399.34 -390.377
Other Equity, Total -0.636 -0.978 -1.146 -0.855 -0.613
Total Liabilities & Shareholders’ Equity 265.096 273.003 248.017 244.815 240.288
Total Common Shares Outstanding 47.507 47.253 47.201 47.141 47.081
Other Current Liabilities, Total 0.041
Intangibles, Net 7.344 7.5
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -16.709 -7.471 2.864 -9.665 -8.137
Cash From Operating Activities 17.687 29.04 17.572 -7.183 -0.412
Cash From Operating Activities 3.981 2.965 2.383 1.744 1.426
Non-Cash Items 41.624 39.7 18.699 15.398 10.084
Cash Interest Paid 0.109 0.004 0.006 0 2.23
Changes in Working Capital -11.209 -6.154 -6.374 -14.66 -3.785
Cash From Investing Activities -36.206 -3.501 -17.16 10.615 -67.027
Capital Expenditures -7.596 -7.915 -2.626 -2.616 -2.678
Other Investing Cash Flow Items, Total -28.61 4.414 -14.534 13.231 -64.349
Cash From Financing Activities 1.045 9.171 6.441 5.26 58.863
Financing Cash Flow Items -2.607 -2.013 -0.191 -0.026 -0.71
Issuance (Retirement) of Stock, Net 3.652 11.184 6.632 5.286 77.105
Issuance (Retirement) of Debt, Net 0 0 -17.532
Foreign Exchange Effects
Net Change in Cash -17.474 34.71 6.853 8.692 -8.576
Cash Taxes Paid 0 0.379 0 0
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -7.495 -16.709 -22.631 -16.054 -7.091
Cash From Operating Activities 7.86 17.687 10.712 6.611 3.468
Cash From Operating Activities 1.158 3.981 2.942 1.928 0.873
Non-Cash Items 9.619 41.624 32.925 22.812 10.805
Cash Interest Paid 0
Changes in Working Capital 4.578 -11.209 -2.524 -2.075 -1.119
Cash From Investing Activities 2.8 -36.206 -14.477 -13.666 -10.669
Capital Expenditures -8.913 -7.596 -6.471 -5.062 -3.081
Other Investing Cash Flow Items, Total 11.713 -28.61 -8.006 -8.604 -7.588
Cash From Financing Activities 0.107 1.045 0.44 0.752 0.503
Financing Cash Flow Items -2.118 -2.607 -2.6 -1.459 -0.962
Issuance (Retirement) of Stock, Net 2.225 3.652 3.04 2.211 1.465
Net Change in Cash 10.767 -17.474 -3.325 -6.303 -6.698
Issuance (Retirement) of Debt, Net 0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Vericel Corp Ord Company profile

About Vericel Corp

Vericel Corporation is a commercial-stage biopharmaceutical company. The Company specializes in cell therapies and specialty biologics for the sports medicine and severe burn care. It operates in one reportable segment, the research, product development, manufacture, and distribution of cellular therapies for use in the treatment of specific diseases. It markets two autologous cell therapy products in the United States, which includes MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The MACI is an autologous cellularized scaffold product indicated for the repair of symptomatic, single, or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. The Epicel is a permanent skin replacement humanitarian use device (HUD) for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area (TBSA).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Vericel Corp revenues increased 26% to $156.2M. Net loss totaled $7.5M vs. income of $2.9M. Revenues reflect MACI segment increase of 18% to $111.6M, Epicel segment increase of 51% to $41.5M. Net loss reflects Stock-based Compensation in SGA increase from $10M to $26.5M (expense), Other Selling , General Expense increase of 21% to $71.1M (expense).

Equity composition

Common Stock no Par, 3/11, 62.5M auth., 38,618,037 issd. Insiders control approx. 0.63%. IPO: 2/97, 3M shares @ $7 byCowen & Company. 02/10 1-for-8 reverse split. 10/13, 1-for-20 Reverse Stock split.

Industry: Biopharmaceuticals

64 Sidney St
CAMBRIDGE
MASSACHUSETTS 02139-4170
US

Income Statement

  • Annual
  • Quarterly

News

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

Cable coils near lows ahead of Fed and BoE rate decisions

It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

14:16, 19 September 2023

FTSE 100 Technical Outlook - 18 September 2023

In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

06:55, 19 September 2023
View of the City of London’s illuminated financial district skyline at dusk

Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

13:46, 15 September 2023

People also watch

US100

14,780.30 Price
+0.570% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 1.8

BTC/USD

26,648.10 Price
-0.080% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

ETH/USD

1,598.70 Price
+0.380% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

Oil - Crude

90.94 Price
+1.510% 1D Chg, %
Long position overnight fee 0.0349%
Short position overnight fee -0.0568%
Overnight fee time 21:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading